Stock Price
72.94
Daily Change
-0.77 -1.04%
Monthly
-37.25%
Yearly
-3.44%
Q4 Forecast
71.30

EPS Reference Time Actual Consensus Previous
2026-11-03 FY2026Q3 PM 1.01 0.23 0.16
2026-07-29 FY2026Q2 PM 0.36 0.01 0.29
2026-04-30 FY2026Q1 PM -0.30 -0.11 0.17
2026-02-24 FY2025Q4 PM 0.20 0.38 0.26
2025-11-04 FY2025Q3 PM 0.16 0.17 0.41



Peers Price Chg Day Year Date
Acadia Pharmaceuticals 18.75 0.61 3.36% -21.94% Nov/13
Aurora Cannabis 7.05 -0.07 -0.98% 16.72% Nov/13
ANI Pharmaceuticals 71.44 0.38 0.53% -14.97% Nov/13
Ardelyx 3.09 -0.03 -0.96% -47.27% Nov/13
BioMarin Pharmaceutical 57.23 0.53 0.93% 4.57% Nov/13
Bristol-Myers Squibb 63.43 1.11 1.78% 35.97% Nov/13
Corcept Therapeutics 72.94 -0.77 -1.04% -3.44% Nov/13
Knight Therapeutics 12.06 0.01 0.08% 96.42% Nov/13
J&J 285.75 2.23 0.79% 45.84% Nov/13
Eli Lilly 1,445.58 2.08 0.14% 41.49% Nov/16

Indexes Price Day Year Date
USND 25136 -229.82 -0.91% 9.76% Nov/13
US Index 2000 2790 -8.57 -0.31% 16.84% Nov/13

Corcept Therapeutics traded at $72.94 this Friday November 13th, decreasing $0.77 or 1.04 percent since the previous trading session. Looking back, over the last four weeks, Corcept Therapeutics lost 37.25 percent. Over the last 12 months, its price fell by 3.44 percent. Looking ahead, we forecast Corcept Therapeutics to be priced at 71.30 by the end of this quarter and at 66.59 in one year, according to Trading Economics global macro models projections and analysts expectations.

Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the steroid hormone cortisol. The Company has marketed the cortisol modulator Korlym in the United States for the treatment of patients with a form of hypercortisolism known as endogenous Cushing’s syndrome. Cortisol activity can be modulated effectively by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s active ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its portfolio of selective cortisol modulators consists of four structurally distinct series, including relacorilant, exicorilant and miricorilant. These compounds bind to GR but not the progesterone, estrogen or androgen receptors.